ROCHE HLDG DR - Dusseldorf Stock Exchang (RHO5 DU) stock market data APIs
€290.2969
17.71(6.1%)
as of October 23, 2025
Try our APIs with
free plan!
ROCHE HLDG DR - Dusseldorf Stock Exchang Financial Data Overview
Price chart is built with
Anychart
There is no Profile data available for RHO5.DU.
Prev. Close
290.2969
Open
308.0094
High
308.0094
Low
290.6127
52 wk Range
235.4817-314.7
Market Cap
312 681 M
Dividends (Yield)
0.0415
* We provide hundreds of fields of fundamental data, including EBITDA, P/E ratio, PEG ratio, trailing P/E, shareholders, insider transactions, technical metrics, dividends, splits, earnings, and more. Check out our Fundamental Data API.
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
Get ROCHE HLDG DR - Dusseldorf Stock Exchang data using free add-ons & libraries
Get ROCHE HLDG DR - Dusseldorf Stock Exchang Fundamental Data
ROCHE HLDG DR - Dusseldorf Stock Exchang Fundamental data includes:
- Net Revenue:
- EBITDA:
- Earnings Per Share: 0
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
$
59.99
/mo.
End-of-day & Earnings data
What’s included:
- Latest Release: NaN
- EPS/Forecast: NaN
Get ROCHE HLDG DR - Dusseldorf Stock Exchang End-of-day data
EOD Historical Data package for
$
19.99
/mo.
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
ROCHE HLDG DR - Dusseldorf Stock Exchang News
New
Prothena Corporation plc (PRTA): A Bull Case Theory
This stock is one of several featured in our latest research. For more small-cap opportunities with asymmetric return potential, read our free article: 10 High-Potential Small-Caps With Market Cap Und...
Roche's Gazyva Secures FDA Nod for Label Expansion in Lupus Nephritis
Roche RHHBY announced that the FDA has approved a regulatory filing seeking the label expansion of Gazyva/Gazyvaro (obinutuzumab) to treat adult patients with active lupus nephritis (LN) who are recei...
AstraZeneca's Cancer Breakthrough: Enhertu Data Sparks New Hope for Early Breast Cancer Cure
This article first appeared on GuruFocus. AstraZeneca (NASDAQ:AZN) and Daiichi Sankyo just delivered one of the most consequential oncology updates of the year. Their breast cancer therapy, Enhertu, ...
Top 1% Celcuity Stock Shoots To Record High On Roche-Rivaling Breast Cancer Results
Celcuity stock shot to a record high Monday after the company said its experimental drug delayed breast cancer progression for over a year. Continue Reading View comments
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
- Price stability: Locked-in rates for subscribed users, never changing
All-In-One
$99.99/mo.
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.
